New Jersey resident Jeff Borghoff, a patient in Biogen's failed clinical trial for Alzheimer's, was left heartbroken when he heard the news the experimental treatment was unlikely to work.
Every month, a car would pick up Jeff Borghoff at his home in Forked River, New Jersey, and drive him to the Advanced Memory Research Institute of New Jersey. There, doctors would help him settle into a comfortable chair and hook him up to an IV.
The bad news was the companies developing aducanumab, Biogen and its partner Eisai, announced earlier that day that they halted two late-stage trials of the experimental drug after an independent group's analysis showed that the trials were unlikely to"meet their primary endpoint." Salim Syed, senior biotech analyst at Mizuho Securities who covers the stock, said Biogen's failure was a shock to many as the Alzheimer's treatment showed promise and followed the widely accepted theory that beta amyloid was responsible for the disease.
The FDA has approved four Alzheimer's drugs, all of which are aimed at helping symptoms, not actually reversing or slowing the disease itself. That's not to say people aren't trying. The National Institutes of Health alone expects to invest $1.46 billion on Alzheimer's research this year, almost three times the $562 million spent in 2014.
"She said, 'I'm sorry to tell you, Jeffrey has Alzheimer's. All the tests came back and he's early in the stages. Get your affairs in order,"' Kim recalls the doctor saying. Major drug companies such as Pfizer, Johnson & Johnson, Eli Lilly and Merck have ended their attempts to treat Alzheimer's by targeting beta amyloid after failing to produce good results. In January, Swiss drugmaker Roche announced that it was ending two-late stage trials for Alzheimer's that also targeted beta amyloid. It's still testing another amyloid drug at a higher dose.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Facebook: Our AI Tools Failed to Catch New Zealand Attack VideoFacebook said the gruesome video of the New Zealand mosque shootings revealed gaps in its handling of live broadcasts by users, but pushed back against the idea of setting up a time delay.
Read more »
Facebook says its artificial intelligence systems failed to detect New Zealand shooting videoFacebook’s vice president of integrity, Guy Rosen, said “this particular video did not trigger our automatic detection systems.”
Read more »
Facebook: Our AI failed to catch the New Zealand shooter videoFacebook says its AI failed to catch the New Zealand shooter video. The shooter livestreamed 17 minutes of the horrific attack -- which left 50 people dead -- on the site.
Read more »
U.S. announces first new North Korea sanctions since failed summitThe United States on Thursday sanctioned two China-based shipping companies it s...
Read more »
U.S. imposes first new North Korea sanctions since failed summitThe United States imposed sanctions on Thursday on two Chinese shipping companie...
Read more »
Facebook admits its AI failed to flag the New Zealand terror attack livestreamFacebook admits its AI failed to flag the New Zealand terror attack livestream.
Read more »
Facebook admits its AI failed to flag the NZ terror attack livestreamFacebook admits its AI failed to flag the New Zealand terror attack livestream.
Read more »
The Latest: Facebook: AI failed to detect NZ videoCHRISTCHURCH, New Zealand (AP) — The Latest on the mosque attacks in New Zealand (all times local): 11:30 p.m. Facebook says its artificial intelligence systems failed to automatically...
Read more »
Irish pride — and a dash of politics — at largest St. Patrick's Day parade in U.S.Brexit was somewhat the talk, but nothing could put a damper on the largest American celebration of Irish heritage on Saturday, with tens of thousands of marchers following a painted green line up Fifth Avenue for the six-hour procession.
Read more »